Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

MSLP, BSDM - MusclePharm; Stock-PR.com Stock Watch for Tomorrow October 25th 2010

|Includes: Perseon Corporation (PRSN)

 

Stock-PR Reporting

stockpr_logo-site

 

 

FREE Daily Stock Alerts From Stock-PR.com

 

signup3m

________________________________________

MusclePharm(NYSE:R) Corporation (OTCBB:MSLP - News), sponsered Jake Shields won his UFC debut, but struggled to get it, pulling off a split decision over Martin Kampmann. Shields seemed to be completely gassed by the middle of the second round and struggled to do much in the final seven or eight minutes.

 

But judges had it 30-27 and 29-28 for Shields and 29-28 for Kampmann, apparently qualifying Shields for a shot at the winner of the welterweight title bout at UFC 124 on Dec. 11 between champion Georges St. Pierre and Josh Koscheck. Yahoo! Sports’ Kevin Iole, Dave Doyle and Dave Meltzer all had it 29-28 Kampmann.

http://sports.yahoo.com/mma/blog/cagewriter/post/Jake-Shields-grapples-his-way-to-a-split-decisio;_ylt=A9j8eDk.0sNMlegAQQSrpph4?urn=mma-279371

The last 5days chart for MSLP:

http://crwewallstreet.com/img/mslp_chart1.jpg

More:

MSLP announced Bodybuilding.com selected the Company as the Supplement Company of the Month for October.Bodybuilding.com recognizes leading supplement companies with products and services that are making a positive impact on the industry and their consumers each month.

Jeremy Deluca, Bodybuilding.com’s President, commented: “MSLP’s ads are in all the magazines with some of the biggest names not only in bodybuilding, but the entire sports world. You see their logo on every MMA event and their products are amongst the most popular in the industry today. Bodybuilding.com is recognizing MusclePharm for their accomplishments and their loyal customer base by featuring them as the Supplement Company of the Month.”

MusclePharm is presently preparing their application for Recon to be added to the Medicaid formulary, beginning in New York State for people diagnosed with HIV and AIDS as well as nation-wide Veterans Administration therapeutic formularies. In addition, MusclePharm is exploring the distribution of MusclePharm products, such as Recon, to people living with HIV in developing nations thru The Global Fund to Fight AIDS, Tuberculosis and Malaria, and The Presidents Emergency Plan for AIDS Relief (PEPFAR).”

MSLP ’s top management has extensive experience in the sports world and has harnessed this drive and focus into building a business to benefit its customers and help Fuel The Athlete Inside. MSLP is a fast-growing developer and manufacturer of safe, scientifically approved, nutritional supplements that are free of banned substances and tested by athletes. They are designed to help athletes, bodybuilders, weightlifters and fitness enthusiasts improve their performance. Each and every MSLP product is the end result of an advanced six-stage research and testing protocol involving the expertise of top nutrition scientists. In addition, the products have been field-tested by more than 100 elite professional athletes from the NFL, MMA, MLB and elsewhere. To date, MSLP has developed six products: ASSAULT, BATTLE FUEL, BULLET PROOF, COMBAT POWDER, RECON and SHRED MATRIX. Two additional products are due in stores in 2010. MSLP products offer up to twice as much of the active ingredients per serving as competing products and incorporate a proprietary mix of ingredients not available elsewhere. MSLP was founded in 2008 and is based in Aurora, Colorado.

http://crwewallstreet.com/img/mslp_pic_03.jpg

To Complete, In the end of the last week, shares of MSLP, MusclePharm, increased $0.14 (+20.00%), up to $0.84!

More about MSLP at: www.musclepharm.com

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

http://crwewallstreet.com/img/bsdm-logo.jpg

BSD Medical Corporation (NASDAQ:BSDM - News) (the “Company” or “BSD”) announced publication in Internal Medicine News Digital Network of new data from the ESHO/EORTC Soft Tissue and Bone Sarcoma Group (STBSG) Phase III clinical study of hyperthermia. (Freeman, S. [10/5/2010]. Regional Hyperthermia Plus Chemo Helps High-Risk, Nonextremity, Soft Tissue Sarcomas. Internal Medicine News Digital Network. Retrieved from http://www.internalmedicinenews.com). The new data were presented by Dr. R. D. Issels, Klinikum Grosshadern at the Ludwig-Maximilians University of Munich, at the biennial meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO), which was held in Barcelona, Spain on September 12-16, 2010. The data demonstrated that the addition of hyperthermia to chemotherapy significantly increases progression-free and disease-free survival rates in patients with high-risk nonextremity sarcomas who have macroscopically complete surgical resection.

The Phase III STBSG trial involved 341 patients who were treated at leading research centers in Europe and the United States and used the BSD-2000 Hyperthermia System to deliver hyperthermia combined with chemotherapy for the treatment of high-risk, soft-tissue sarcoma cancer patients. The main findings of the sarcoma trial were recently published in The Lancet Oncology. (Issels RD, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft tissue sarcoma: a randomised phase 3 multicentre study. 2010;11:561-570. doi:10.1016/S1470-2045(10)70071-1). The data demonstrated improved overall survival if regional hyperthermia (NYSE:HT) was added to chemotherapy (etoposide, ifosfamide, and doxorubicin [EIA]) treatment, for patients who received the complete treatment. The study also demonstrated that regional hyperthermia combined with chemotherapy (CT) improved tumor reduction, disease-free survival, and time to disease progression.

More about BSDM at: www.BSDMedical.com

 

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings, Inc. (OTCPK:CRWE) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (OTCQB:MSLP)

Sign Up For Free Stock Alerts At http://stock-pr.com/signup

http://stock-pr.com/img/stock-pr_buscard.jpg

________________________________________

Be Sure To Visit stock-pr.ning.com

**********************************************************************

The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.